AMPD1 rs1760944: Promoter Variant and Exercise Physiology
rs1760944 is a single nucleotide polymorphism located in the promoter region of the AMPD1 gene, which encodes the skeletal muscle enzyme adenosine monophosphate deaminase. This variant has been investigated in preliminary fitness genomics research for its potential role in modulating AMPD1 gene expression, cardiorespiratory training adaptations, and post-exercise muscle fatigue. While the AMPD1 locus is central to muscular energetic pathways, the clinical and phenotypic evidence specifically linked to rs1760944 remains limited.
What each genotype means
Typical enzyme activity
This genotype represents the most common form of the AMPD1 gene, which is associated with standard production of the AMP deaminase enzyme in skeletal muscle. Individuals with this profile are not expected to have the reduced enzyme activity linked to exercise-induced muscle fatigue or cramping often discussed in research regarding this gene.
This is the most common genotype in most global populations, carried by the majority of individuals.
Reduced enzyme activity carrier
Carrying one copy of the T allele may result in a partial reduction of AMP deaminase enzyme activity in skeletal muscle. While many people with this genotype remain asymptomatic, some research suggests a potential for increased susceptibility to exercise-induced fatigue or muscle soreness compared to those without the variant.
This genotype is found in a significant portion of European populations, occurring in roughly 1 in 3 to 1 in 4 individuals.
Likely reduced enzyme activity
This genotype is associated with a significant reduction or absence of functional AMP deaminase enzyme in skeletal muscle. While some individuals with this profile remain asymptomatic, others may experience exercise intolerance, muscle pain, or cramping following strenuous physical activity. Please discuss any concerns regarding exercise performance or muscle recovery with your healthcare provider.
This genotype is relatively rare, observed in approximately 2% of individuals of European ancestry.
Genomic Location and Variant Biology
The single nucleotide polymorphism rs1760944 is situated in the 5' regulatory promoter region of the AMPD1 gene on human chromosome 1. Promoter variants do not alter the amino acid sequence of a protein directly; instead, they often influence transcriptional efficiency by altering transcription factor binding affinities or chromatin structure. In skeletal muscle, regulatory variants upstream of AMPD1 can modulate baseline transcription rates or responsiveness to physiological stimuli such as high-intensity physical exertion. While rs1760944 is less frequently studied than the canonical coding nonsense mutation rs17602729 (c.34C>T), researchers hypothesize that regulatory changes at rs1760944 may contribute to subtle inter-individual variations in muscle enzyme levels rather than a complete loss of function.
The Role of AMPD1 in Skeletal Muscle Metabolism
The AMPD1 gene encodes adenosine monophosphate deaminase 1, a key metabolic enzyme highly enriched in skeletal muscle fast-twitch fibers. During high-intensity exercise or rapid muscle contraction, adenosine triphosphate (ATP) is rapidly broken down to adenosine diphosphate (ADP) and then adenosine monophosphate (AMP). AMPD1 catalyzes the irreversible deamination of AMP into inosine monophosphate (IMP) and ammonia, a central step in the purine nucleotide cycle. This reaction prevents the inhibitory accumulation of AMP and ADP, helping maintain the critical ATP-to-ADP ratio needed for continuous power generation. Deficiencies or significant reductions in AMPD1 enzyme activity have historically been linked to delayed strength recovery, early muscular fatigue, and exertion-related cramping.
Current Scientific Evidence and Phenotypic Associations
Current evidence associating rs1760944 with muscular performance traits is classified as limited. Small-scale candidate gene investigations and exploratory exercise cohorts have examined whether promoter variants in AMPD1 correlate with differences in cardiorespiratory fitness (such as VO2 max adaptations) and perceived post-exercise fatigue. However, results across replication cohorts are mixed. Much of the robust biochemical literature on muscular fatigue in this pathway focuses on the null mutation rs17602729. It remains unresolved whether observed associations with rs1760944 represent independent functional promoter effects or partial linkage disequilibrium with other functional variants within the AMPD1 locus. Broad, multi-ancestry genome-wide association studies (GWAS) have not established a definitive, large-effect link for rs1760944.
Ancestry and Population Distributions
The distribution of rs1760944 alleles varies substantially across global ancestral populations. In European populations, the minor allele frequency (typically represented by the A or alternate allele in public catalogs) is moderately common, estimated between 0.20 and 0.35. Frequencies can differ significantly in East Asian, South Asian, and African reference populations captured in genomic repositories like gnomAD and 1000 Genomes. Because allele frequencies and genomic linkage patterns vary across ancestral groups, findings from candidate gene studies performed predominantly in cohorts of European descent cannot be generalized reliably to other populations without specific validation.
Practical Considerations: What This Information Means for You
Information regarding your rs1760944 genotype should be viewed as an educational glimpse into muscle metabolism research, not a medical diagnosis or a definitive predictor of athletic capacity. Having a variant allele in a promoter region does not mean an individual cannot achieve high levels of aerobic or anaerobic fitness. Elite athletic performance, exercise recovery, and cardiorespiratory conditioning are polygenic traits shaped by thousands of common genetic variants alongside training consistency, sleep, and nutrition. If you experience persistent exercise intolerance, severe muscle cramping, or unexplained weakness, speak to a physician or sports medicine specialist to evaluate standard clinical and metabolic causes.
How common is this variant?
The minor allele (A) for rs1760944 has an estimated frequency of approximately 0.20 to 0.35 in European populations, with differing baseline frequencies across other ancestral cohorts in large genomic databases.
Frequently asked questions
Does having the rs1760944 variant cause myoadenylate deaminase deficiency?
No. Classical myoadenylate deaminase (AMPD1) deficiency is typically caused by severe loss-of-function mutations, most notably the nonsense mutation rs17602729 (c.34C>T). rs1760944 is a promoter variant that may at most subtly modulate gene expression levels rather than abolishing the functional protein.
Can rs1760944 determine whether I should focus on endurance or sprint training?
No. Athletic traits such as endurance and sprint capacity are polygenic, involving thousands of genetic variants alongside training, diet, and recovery. A single promoter variant provides insufficient predictive power to design or limit an athletic training regimen.
Does this genetic variant cause muscle cramping after every workout?
Not necessarily. While some studies explore whether AMPD1 alterations increase perceived muscle soreness or fatigue, cramping is multifactorial and primarily influenced by hydration, electrolyte balance, conditioning level, and workout intensity. Most carriers of rs1760944 exercise without chronic or unusual cramping.
Can a genetic test for rs1760944 be used for clinical diagnosis?
No, rs1760944 is currently categorized as a research trait variant with limited evidence and is not an approved diagnostic marker for any metabolic or muscular disorder. Clinical assessment of muscle weakness or metabolic myopathy requires comprehensive medical evaluation by a licensed healthcare provider.
Sources & further reading
Educational information only, last refreshed 9/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1760944?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in AMPD1
Located adjacent to the classic nonsense locus of adenosine monophosphate deaminase 1, this variant tracks exercise-induced muscle cramping, early fatigue, and post-exercise recovery phenotypes.
This SNP is associated with autism risk and may influence physiological responses to stress-related environmental factors.